18 October 2023 - TLV has produced a health economic knowledge base for the regions for Spinraza (nusinersen sodium) for the treatment of patients with type 5q spinal muscular atrophy.

TLV has previously published a health economic assessment of Spinraza. Within the context of the current case, the NT Council has ordered an updated health economic assessment of the TLV relating to Spinraza.

Read TLV News [Swedish]